The micelles reversed multidrug resistance by down-regulating P-glycoprotein expression and increasing plasma membrane fluidity.39 Similarly, Lu et al.39 demonstrated that paclitaxel combined with honokiol nanosuspensions, encapsulated in thermosensitive hydrogels, allowed for sustained and targeted drug release at the tumor site.40 Honokiol has also shown benefits as a complementary therapy in patients with paclitaxel-resistant tumors, particularly when administered intravenously.19 Here, ABCB1 is linked to neoplasm.